Browse our 1,000+ Publications
Latest Publications
Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease
Parsons E et al.
Frontiers in Immunology
January 2026
Authors and Affiliates
Emily Parsons, Zhongyan Lu, Stephanie A. Richard, Amanda Zelkoski, Janifer Le, Naraen Palanikumar, Phuong Nguyen, Camille Alba, Gauthaman Sukumar, John Rosenberger, Xijun Zhang, Timothy H. Burgess, Rhonda Colombo, Katrin Mende, Catherine Berjohn, Nursat Epsi, Brian K. Agan, David Tribble, David A. Lindholm, Clifton L. Dalgard, Simon D. Pollett, Allison M. W. Malloy* and EPICC COVID-19 Cohort Study Group
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.
Miller et al.
BMJ
January 2026
Authors and Affiliates
Natalie J Miller, Christina Baik, Joel W Neal, Fangdi Sun, Rafael Santana-Davila, Sylvia Lee, Keith D Eaton, Renato G Martins, Cristina Rodriguez, Heather Wakelee, Sukhmani K Padda, Elena Sotillo, Eric Q Konnick, Alex Camai, Tatyana Pisarenko, Viswam S Nair, Crystal Mackall, A McGarry Houghton, Shin-Heng Chiou, Diane Tseng
Three‑year follow‑up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL‑3
Izutsu K, et al.
International Journal of Hematology
January 2026
Authors and Affiliates
Koji Izutsu1 · Daigo Akahane2
· Tomomi Toubai3
· Toko Saito4
· Yuko Mishima5
· Tomoaki Fujisaki6
·
Momoko Nishikori7
· Takahiro Kumode8
· Youko Suehiro9
· Kenji Ishitsuka10 · Poliana Patah11 · Ami Takahashi12 ·
Barbara D’Angelo Månsson13 · Elena Favaro13 · Noriko Fukuhara14
1 Department of Hematology, National Cancer Center
Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
2 Department of Hematology, Tokyo Medical University,
Tokyo, Japan
3 Department of Internal Medicine III, Division of Hematology
and Cell Therapy, Faculty of Medicine, Yamagata University,
Yamagata, Japan
4 Department of Hematology and Cell Therapy, Aichi Cancer
Center, Nagoya, Japan
5 Department of Hematology Oncology, Cancer Institute
Hospital, Japanese Foundation for Cancer Research, Tokyo,
Japan
6 Department of Hematology, Japan Red Cross Society,
Matsuyama Red Cross Hospital, Matsuyama, Japan
7 Department of Hematology, Graduate School of Medicine,
Kyoto University, Kyoto, Japan
8 Department of Hematology and Rheumatology, Kindai
University, Osaka, Japan
9 Department of Hematology and Cell Therapy, National
Hospital Organization Kyushu Cancer Center, Fukuoka,
Japan
10 Department of Hematology and Rheumatology, Kagoshima
University, Kagoshima, Japan
11 AbbVie, North Chicago, IL, USA
12 Genmab, Tokyo, Japan
13 Genmab, Copenhagen, Denmark
14 Department of Hematology, Tohoku University, Sendai,
Japan
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Einsele H, et al.
Lancet Oncology
January 2026
Authors and Affiliates
Hermann Einsele, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels WCJ van de Donk, Surbhi Sidana, Albert Oriol, Yael C Cohen,Simon J Harrison, María-Victoria Mateos, Joaquín Martínez-López, Paolo Corradini, Lionel Karlin, Diana Chen, Quanlin Li, Tzu-min Yeh,Katherine Li, Vicki Plaks, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Jordan M Schecter, Nikoletta Lendvai,Mythili Koneru, Nitin Patel, Erika Florendo, Phoebe Joy Ho, Rakesh PopatUniversitätsklinikumWürzburg, Medizinische Klinikund Poliklinik II, Würzburg,Germany (Prof H Einsele MD);Cancer Center ClinicaUniversidad de Navarra, CIMA,IDISNA, Pamplona, Spain(Prof J San-Miguel MD PhD);Medical College of Wisconsin,Milwaukee, WI, USA(Prof B Dhakal MD); Serviced’Hématologie, CHU HotelDieu, Nantes, France(Prof C Touzeau MD); CRCINA,INSERM, CNRS, Universitéd’Angers, Université de Nantes,Nantes, France (Prof C Touzeau);Site de Recherche Intégrée surle Cancer (SIRIC), ILIAD, INCA-DGOS-Inserm_12558, Nantes,France (Prof C Touzeau); Serviced’Hématologie et ThérapieCellulaire, Hôpital La Milétrie(Prof X Leleu MD PhD), andCentre d’Investigation CliniqueINSERM 1402 (Prof X Leleu),Poitiers University Hospital,Poitiers, France; AmsterdamUniversity Medical Center, VrijeUniversiteit Amsterdam,Amsterdam, Netherlands(Prof N W C J van de Donk MD PhD);Stanford University School ofMedicine, Stanford, CA, USA(Prof S Sidana MD); InstitutCatalà d’Oncologia(A Oriol MD PhD), and InstitutJosep Carreras (A Oriol),Hospital Germans Trias i Pujol,Badalona, Spain; Tel-AvivSourasky (Ichilov) MedicalCenter, Gray Faculty of Medicaland Health Sciences, Tel AvivUniversity, Tel Aviv, Israel(Prof Y C Cohen MD); PeterMacCallum Cancer Centre,Melbourne and RoyalMelbourne Hospital, Melbourne, VIC, Australia(Prof S J Harrison MBBS PhD);Translation Laboratory, Centreof Excellence in CellularImmunotherapy, PeterMacCallum Cancer Centre,Melbourne, VIC, Australia(Prof S J Harrison); Sir PeterMacCallum Department ofOncology, University ofMelbourne, Parkville, VIC,Australia (Prof S J Harrison);University Hospital ofSalamanca–IBSAL–CIC–CIBERONC, Salamanca, Spain(Prof M-V Mateos MD PhD);Hospital 12 de Octubre,Complutense University CNIO,MIC, Madrid, Spain(Prof J Martínez-López MD PhD);Fondazione IRCCS IstitutoNazionale dei Tumori Milano,University of Milano, Milan,Italy (Prof P Corradini MD);Centre Hospitalier Lyon Sud,Pierre-Bénite, France(L Karlin MD); Johnson &Johnson, Shanghai, China(D Chen MS); Johnson &Johnson, Apex, NC, USA(Q Li MS); Johnson & Johnson,Raritan, NJ, USA (T-m Yeh MS,A Ghosh MD PhD,J M Schecter MD,N Lendvai MD PhD); Johnson &Johnson, Spring House, PA,USA (K Li MS, V Plaks LLB PhD);Johnson & Johnson, Zug,Switzerland (A Slaughter PhD);Johnson & Johnson, BuenosAires, Argentina(C Lonardi PharmD); Johnson &Johnson, Beerse, Belgium(N Benachour MS); Johnson &Johnson, Neuss, Germany(M Vogel MD PhD); LegendBiotech USA, Somerset, NJ,USA (M Koneru MD PhD,N Patel BM BCh,E Florendo MSN); Royal PrinceAlfred Hospital, Sydney, NSW,Australia(Prof P J Ho MBBS DPhil);University of Sydney, Sydney,NSW, Australia (Prof P J Ho);University College LondonHospitals, NHS FoundationTrust, London, UK(R Popat MD PhD)
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial
Strati P, et al.
Nature Cancer
January 2026
Authors and Affiliates
Paolo Strati 1 , Lori Leslie2, Parveen Shiraz 3, Lihua E. Budde 4,Olalekan O. Oluwole5, Matthew Ulrickson 6, Aravind Ramakrishnan7,Teresa Zhang8, Jennifer Sun8, Francesca Milletti8, Justyna Kanska8, Rhine Shen8,Frank Neumann8, Hairong Xu8 & Krish Patel9
1Department of Lymphoma and Myeloma and Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center,Houston, TX, USA. 2Indolent Lymphoma and CLL Research Programs, John Theurer Cancer Center, Hackensack, NJ, USA. 3Division of Blood and MarrowTransplantation and Cellular Therapy, Stanford University, Stanford, CA, USA. 4Department of Hematology and Hematopoietic Cell Transplantation,City of Hope National Medical Center, Duarte, CA, USA. 5Division of Hematology Oncology, Vanderbilt University Cancer Center, Nashville, TN, USA.6Section of Hematology, Stem Cell Transplant, and Cellular Therapy, Banner MD Anderson Cancer Center, Gilbert, AZ, USA. 7Center for Blood Cancersand Oncology, Texas Transplant Physician Group, Austin, TX, USA. 8Kite, a Gilead Company, Santa Monica, CA, USA. 9Lymphoma Program andHematologic Malignancies and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, USA
Shared TCRs in peripheral blood offer robust celiac disease classification independent of gluten intake
Rebecca Elyanow, et al.
bioRxiv
Pre-Print
December 2025
Authors and Affiliates
Rebecca Elyanow, Rok Seon Choung, Eric V. Marietta, Ramit Bharanikumar, Wenyu Zhou, Haiyin Chen-Harris, Bryan Howie, Harlan S Robins, Susan L. Neuhausen, Joseph A. Murray
Venetoclax-Dexamethasone VersusPomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Popat R, et al.
Journal of Clinical Oncology
December 2025
Authors and Affiliates
Rakesh Popat, MD, PhD1 ; Meral Beksac, MD2 ; Meletios A. Dimopoulos, MD3,4 ; Moshe E. Gatt, MD5 ; Francesca Gay, MD6 ;Jae-Cheol Jo, MD, PhD7 ; Prashant Kapoor, MD8 ; Eirini Katodritou, MD, PhD9 ; K. Martin Kort¨um, MD10 ; Silvia Ling, PhD, MBBS11 ;Chandramouli Nagarajan, MD12 ; Kenshi Suzuki, MD, PhD13; Lugui Qiu, MD14; Maika Onishi, MD15; Grace Ku, MD15 ; Monique Dail, PhD15 ;Nabanita Mukherjee, PhD16; Jeremy A. Ross, PhD16; Mohamed Ali Badawi, PhD16; Mary Jean Fusco, MD16; Edyta Dobkowska, MD17;Emma Arriola, PhD18; Orlando F. Bueno, MD, PhD16; Nizar J. Bahlis, MD19 ; Shinsuke Iida, MD20 ; Philippe Moreau, MD21; Jason Valent, MD22; andMar´ıa-Victoria Mateos, MD, PhD231Haematology Department, University College London Hospitals NHSFoundation Trust, London, United Kingdom2Department of Hematology, Ankara University, Ankara, Turkey3Department of Clinical Therapeutics, School of Medicine, National andKapodistrian University of Athens, Athens, Greece4Department of Medicine, Korea University, Seoul, South Korea5Department of Hematology, Hadassah Hebrew University MedicalCenter, Jerusalem, Israel6Division of Hematology 1, Department of Biotechnology and HealthScience, Azienda Ospedaliero-Universitaria Citt `a della Salute e dellaScienza, University of Torino, Torino, Italy7Department of Hematology and Oncology, Ulsan University Hospital,University of Ulsan College of Medicine, Ulsan, Korea8Division of Hematology, Mayo Clinic, Rochester, MN9Department of Hematology, Theagenion Cancer Hospital, Thessaloniki,Greece 10Department of Internal Medicine II, W¨urzburg University Hospital,University of W¨urzburg, W¨urzburg, Germany11Department of Haematology, Liverpool Hospital, Sydney, NSW,Australia12Department of Haematology, Singapore General Hospital, Singapore,Singapore13Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,Tokyo, Japan14National Clinical Research Center for Hematological Disorders & StateKey Laboratory of Experimental Hematology, Institute of Hematologyand Blood Diseases Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Tianjin, China15Genentech Inc, South San Francisco, CA16AbbVie Inc, North Chicago, IL17Pharmacyclics Switzerland GmbH, An AbbVie Company,Schaffhausen, Switzerland18AbbVie, Maidenhead, United Kingdom19Arnie Charbonneau Cancer Institute, University of Calgary, Calgary,AB, Canada20Department of Hematology and Oncology, Nagoya City UniversityGraduate School of Medical Sciences, Nagoya, Japan21Department of Hematology, University Hospital Hˆotel-Dieu, Nantes,France22Department of Hematology and Medical Oncology, Cleveland ClinicFoundation, Taussig Cancer Institute, Cleveland, OH23Haematology Department, University Hospital of Salamanca, Institutode Investigaci ´on Biom´edica de Salamanca and Institute of CancerMolecular and Cellular Biology and CIBERONC, Salamanca, Spain
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa L, et al.
N Engl J Med
December 2025
Authors and Affiliates
Luciano J. Costa, M.D.,1
Nizar J. Bahlis, M.D.,2
Aurore Perrot,
M.D., Ph.D.,3
Ajay K. Nooka, M.D., M.P.H.,4
Jin Lu, M.D.,5
Charlotte Pawlyn, M.B., B.Chir., Ph.D.,6,7
Roberto Mina, M.D.,8
Gaston
Caeiro, M.D.,9
Alain Kentos, M.D.,10 Vania Hungria, M.D., Ph.D.,11
Donna Reece, M.D.,12 Ting Niu, M.D.,13 Anne K. Mylin, M.D.,
Ph.D.,14 Charlotte T. Hansen, Ph.D.,15 Raphael Teipel, M.D.,16
Britta Besemer, M.D.,17 Meletios A. Dimopoulos, M.D.,18,19 Elena
Zamagni, M.D.,20,21 Satoshi Yoshihara, M.D.,22 Kihyun Kim,
M.D.,23 Chang Ki Min, M.D.,24 Paul Geerts, M.D., Ph.D.,25 Elena
Van Leeuwen-Segarceanu, M.D., Ph.D.,26 Agata Tyczynska, M.D.,
Ph.D.,27 Juan Luis Reguera, Ph.D.,28 Magnus Johansson, M.D.,29
Markus Hansson, M.D., Ph.D.,30 Mehmet Turgut, M.D.,31 Mark
Grey, M.D.,32 Surbhi Sidana, M.D.,33 Paula Rodriguez-Otero,
M.D., Ph.D.,34 Joaquin Martinez-Lopez, M.D., Ph.D.,35 Hamza
Hashmi, M.D.,36 Robin Carson, M.D.,37 Rachel Kobos, M.D.,38
Weili Sun, M.D., Ph.D.,39 Kristen Lantz, Ph.D.,37 Anne Seifert,
Ph.D.,40 Deborah Briseno-Toomey, M.S.N.,41 Lisa O’Rourke,
M.S.N.,37 Maria Rubin, Ph.D.,38 Diego Vieyra, Ph.D.,37 Lijuan
Kang, Ph.D.,39 and Maria Victoria Mateos, M.D., Ph.D.42
1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham; 2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; 3 Universite de Toulouse, Centre Hospitalier Universitaire, Service
d’Hematologie, Institut Universitaire du Cancer de Toulouse–
Oncopole, Cancer Research Center of Toulouse, Toulouse,
France; 4Emory University, Winship Cancer Institute, Atlanta; 5Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing; 6Royal Marsden NHS Foundation
Trust, London; 7 Institute of Cancer Research, London; 8Division of Hematology, Department of Molecular Biotechnology
and Health Sciences, AOU Città della Salute e della Scienza di
Torino, University of Turin, Turin, Italy; 9Hospital Privado Universitario de Córdoba Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina; 10Department of
Hematology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium;
11Clinica São Germano, São Paulo; 12Princess Margaret Cancer
Centre, Toronto; 13Department of Hematology, West China
Hospital, Sichuan University, Chengdu; 14Department of Hematology, Rigshospitalet, Copenhagen; 15Department of Hematology, Odense University Hospital, Odense, Denmark;
16Medizinische Klinik und Poliklinik I Universitätsklinikum Carl
Gustav Carus an der Technischen Universität Dresden, Dresden, Germany; 17Department of Internal Medicine II, University
Tübingen, Tübingen, Germany; 18Department of Clinical Therapeutics, National and Kapodistrian University of Athens,
School of Medicine, Athens; 19Department of Medicine, Korea
University, Seoul, South Korea; 20 IRCCS Azienda Ospedaliero–
Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy; 21Dipartimento di Scienze Mediche e Chirurgiche,
Università di Bologna, Bologna, Italy; 22Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan; 23Division of Hematology–Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung
Medical Center, Seoul, South Korea; 24Department of Hematology, College of Medicine, Seoul St. Mary’s Hospital, Catholic
University of Korea, Seoul, South Korea; 25Department of Internal Medicine, Isala Klinieken, Zwolle, the Netherlands; 26Department of Hematology, St. Antonius Hospital Nieuwegein,
Nieuwegein, the Netherlands; 27Department of Hematology
and Transplantology, Medical University of Gdansk; Department of Hematology and Transplantology, University Clinical
Center, Gdansk, Poland; 28Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de l of Hematology, Ondokuz Mayis University, Samsun,
Turkey; 32 Lancashire Haematology Centre, Blackpool Teaching
Hospitals NHS Foundation Trust, Blackpool Victoria Hospital,
Blackpool, United Kingdom; 33 Stanford University School of
Medicine, Palo Alto, CA; 34Cancer Center Clínica Universidad
de Navarra, Pamplona, Spain; 35Hematology Department, Instituto de Investigación Hospital 12 de Octubre, Universidad
Complutense, Centro Nacional de Investigaciones Oncológicas, Centro de Investigación Biomédica en Red de Cáncer, Madrid; 36Memorial Sloan Kettering Cancer Center, New York; 37 Johnson & Johnson, Spring House, PA; 38 Johnson & Johnson,
Raritan, NJ; 39 Johnson & Johnson, Los Angeles; 40 Johnson &
Johnson, High Wycombe, United Kingdom; 41 Johnson & Johnson, Yorba Linda, CA; 42Hospital Universitario de Salamanca,
Instituto de Investigación Biomédica de Salamanca, Instituto
de Biología Molecular y Celular del Cáncer (Universidad de
Salamanca–Consejo Superior de Investigaciones Científicas),
Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain.
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
Falchi L, et al.
Blood
November 2025
Authors and Affiliates
Lorenzo Falchi,1 Anna Sureda,2 Sirpa Leppä,3 Joost S. P. Vermaat,4 Marcel Nijland,5 Jacob Haaber Christensen,6 Sven de Vos,7
Harald Holte,8 Reid W. Merryman,9 Pieternella J. Lugtenburg,10,
* Pau Abrisqueta,11 Kim M. Linton,12 Gauri Sunkersett,13 Daniela Hoehn,14
Ali Rana,14 Aqeel Abbas,14 Jennifer Marek,14 Yi Hao,14 Andrew J. Steele,14 Christopher Morehouse,14 Martin Hutchings,15 and
David Belada16
1
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; 2
Clinical Hematology Department, Institut Catala`
d’Oncologia, L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; 3
Department of Oncology, University of Helsinki and Helsinki University
Hospital Comprehensive Cancer Center, Helsinki, Finland; 4
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands; 5
Department of Hematology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands; 6
Department of Haematology,
Odense University Hospital, Odense, Denmark; 7
Department of Medicine, Hematology/Oncology, Ronald Reagan University of California Los Angeles Medical
Center, Los Angeles, CA; 8
Department of Oncology, Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway; 9
Department of
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 10Department of Hematology, Erasmus MC Cancer Institute, University Medical Center,
Rotterdam, The Netherlands; 11Department of Hematology, Hospital Universitario Vall d’Hebron, Barcelona, Spain; 12Division of Cancer Sciences, The Christie
NHS Foundation Trust, Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom; 13AbbVie, North Chicago, IL; 14Genmab,
Plainsboro, NJ; 15Department of Haematology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; and 164th Department of Internal
Medicine, Haematology, Hospital and Faculty of Medicine, Charles University, Hradec Kralové, ´ Czech Republic